scholarly journals Prostate cancer update from the American Society of Clinical Oncology (ASCO) annual meeting 2016

2016 ◽  
Vol 10 (7-8S) ◽  
pp. 137
Author(s):  
Anil Kapoor
Keyword(s):  
Prostate Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society

Highlights from the 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1–5, 2007

2007 ◽  
Vol 1 (5) ◽  
pp. 269-274
Author(s):  
Latha Shivakumar ◽  
Marissa Shrader ◽  
Sonia Cunningham ◽  
Jorge E. Cortés ◽  
Diane Gambill
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society

Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

2015 ◽  
Vol 33 (9) ◽  
pp. 1078-1085 ◽  
Author(s):  
Matthew J. Resnick ◽  
Christina Lacchetti ◽  
Jonathan Bergman ◽  
Ralph J. Hauke ◽  
Karen E. Hoffman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Oncology ◽  
Cancer Survivorship ◽  
Information Needs ◽  
Specific Antigen ◽  
Cancer Surveillance ◽  
Survivorship Care ◽  
Care Guidelines ◽  
American Society

Purpose The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, prostate cancer surveillance, screening for new cancers, long-term and late functional effects of the disease and its treatment, psychosocial issues, and coordination of care between the survivor's primary care physician and prostate cancer specialist. Methods The American Cancer Society (ACS) Prostate Cancer Survivorship Care Guidelines were reviewed for developmental rigor by methodologists. The American Society of Clinical Oncology (ASCO) Endorsement Panel reviewed the content and recommendations, offering modifications and/or qualifying statements when deemed necessary. Results The ASCO Endorsement Panel determined that the recommendations from the 2014 ACS Prostate Cancer Survivorship Care Guidelines are clear, thorough, and relevant, despite the limited availability of high-quality evidence to support many of the recommendations. ASCO endorses the ACS Prostate Cancer Survivorship Care Guidelines, with a number of qualifying statements and modifications. Recommendations Assess information needs related to prostate cancer, prostate cancer treatment, adverse effects, and other health concerns and provide or refer survivors to appropriate resources. Measure prostate-specific antigen (PSA) level every 6 to 12 months for the first 5 years and then annually, considering more frequent evaluation in men at high risk for recurrence and in candidates for salvage therapy. Refer survivors with elevated or increasing PSA levels back to their primary treating physician for evaluation and management. Adhere to ACS guidelines for the early detection of cancer. Assess and manage physical and psychosocial effects of prostate cancer and its treatment. Annually assess for the presence of long-term or late effects of prostate cancer and its treatment.

The Annual Meeting of the American Society of Clinical Oncology

2010 ◽  
Vol 3 (2) ◽  
pp. E1-E5
Author(s):  
Kristin Garcia ◽  
Aarati Ranganathan ◽  
Robert L. Coleman
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society

scholarly journals Practice Changing Results in RCC come from ASCO 2021

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Marc Matrana ◽  
Erin Pierce ◽  
Erica Doubleday
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Kidney Cancer ◽  
Medical Oncology ◽  
Great Success ◽  
Second Year ◽  
American Society

For the second year in a row, the annual meeting of the American Society of Clinical Oncology (ASCO) was held virtually due to the ongoing COVID-19 pandemic. Nonetheless, the meeting was hailed as a great success and brought much practice changing data in the field of genitourinary medical oncology, including kidney cancer.

scholarly journals Destaques da ASCO 2016 - Imunoterapia no Tratamento do Cancro do Pulmão | Rastreio do Cancro do Pulmão: Considerações Lógicas e Práticas

2018 ◽  
Author(s):  
Maria Bárbara Parente
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Immune Checkpoint ◽  
National Lung Screening Trial ◽  
American Society ◽  
Lung Screening ◽  
Screening Trial

Inibidores de immune checkpoint são uma promessa na luta contra o cancro do pulmão e outros tumores malignos, alterando o microambiente do tumor e bloqueando a evasão ao sistema imunitário. Dois anticorpos anti-PD-1, nivolumab e pembrolizumab, estão aprovados para uso clínico, no cancro do pulmão, doença avançada em segunda linha. Anticorpos PD-L1 tal como atezolizumab e MEDI-4736 estão em desenvolvimento clínico e são alvo atual de vários estudos de fase II/III inclusivamente a decorrer em Portugal; tratamento de segunda linha em doentes com cancro do pulmão de não pequenas células doença avançada tem tido até agora como opção padrão o docetaxel. Desde a publicação dos resultados do National Lung Screening Trial (NLST) em 2011, o rastreio do cancro do pulmão com tomografia computorizada de dose baixa tem sido o centro da investigação, guidelines e discussão geral deste tema. O racional para o screening tem evoluído nos últimos anos, dado que hospitais e outros sistemas de saúde ganharam experiência na implementação de programas de rastreio. O screening também mostra a importância do tabagismo, não apenas como um fator de risco para o cancro, mas também como uma variável que pode afetar drasticamente os resultados do cancro. Estas foram, entre outras, questões discutidas por Especialistas no 2016 ASCO Annual Meeting - American Society of Clinical Oncology, que decorreu em Chicago de 3 a 7 de junho de 2016. Recebido: 20/08/2016 – Aceite: 25/08/2016

Sign in / Sign up

Export Citation Format

Share Document